Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhoea

It is approved in combination with somatostatin analogue therapy
07 Mar 2017
Endocrine and neuroendocrine tumours

On 28 February, 2017 the US Food and Drug Administration (FDA) approved telotristat ethyl (Xermelo) tablets in combination with somatostatin analogue (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhoea that SSA therapy alone has inadequately controlled.

Carcinoid syndrome is a cluster of symptoms sometimes seen in patients with carcinoid tumours. These tumours are rare, and often slow-growing. Most carcinoid tumours are found in the gastrointestinal tract. Carcinoid syndrome occurs in less than 10% of patients with carcinoid tumours, usually after the tumour has spread to the liver. The tumours in these patients release excess amounts of the hormone serotonin, resulting in diarrhoea. Complications of uncontrolled diarrhoea include weight loss, malnutrition, dehydration, and electrolyte imbalance.

Xermelo, in a regimen with SSA therapy, is approved in tablet form to be taken orally three times daily with food. Xermelo inhibits the production of serotonin by carcinoid tumours and reduces the frequency of carcinoid syndrome diarrhoea.

The safety and efficacy of Xermelo were established in a 12-week, double-blind, placebo-controlled trial in 90 adult participants with well-differentiated metastatic neuroendocrine tumours and carcinoid syndrome diarrhoea. These patients were having between four to 12 daily bowel movements despite the use of SSA at a stable dose for at least three months. Participants remained on their SSA treatment, and were randomised to add placebo or treatment with Xermelo three times daily. Those receiving Xermelo added on to their SSA treatment experienced a greater reduction in average bowel movement frequency than those on SSA and placebo. Specifically, 33% of participants randomised to add Xermelo on to SSA experienced an average reduction of two bowel movements per day compared to 4% of patients randomised to add placebo on to SSA.

The most common side effects of Xermelo include nausea, headache, increased levels of the liver enzyme gamma-glutamyl transferase, depression, peripheral oedema, flatulence, decreased appetite and fever. Xermelo may cause constipation, and the risk of developing constipation may be increased in patients whose bowel movement frequency is less than four bowel movements per day. Patients treated with a higher than recommended dosage of Xermelo developed severe constipation in clinical trials. One patient required hospitalization and two other patients developed complications of either intestinal perforation or intestinal obstruction. Patients should be monitored for severe constipation. If a patient experiences severe constipation or severe, persistent or worsening abdominal pain, they should discontinue Xermelo and contact their healthcare provider.

The FDA granted this application fast track designation and priority review. The drug also received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

Xermelo is manufactured by Woodlands, Texas-based Lexicon Pharmaceuticals, Inc.

Last update: 07 Mar 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings